Inactive Instrument

Capricor Therapeutics Inc Stock price Nasdaq

Equities

US14070B1017

Biotechnology & Medical Research

Sales 2024 * 21.4M Sales 2025 * 89.52M Capitalization 213M
Net income 2024 * -33M Net income 2025 * 8M EV / Sales 2024 * 9.93 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 2.37 x
P/E ratio 2024 *
-7.02 x
P/E ratio 2025 *
69.4 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.81%
More Fundamentals * Assessed data
Dynamic Chart
Capricor Therapeutics, Inc. to Present Positive 24-Month Results from its HOPE-2 Open-Label Extension Study at 2024 Muscular Dystrophy Association Clinical & Scientific Conference CI
Transcript : Capricor Therapeutics, Inc., Q4 2023 Earnings Call, Feb 29, 2024
Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Posts Q4 Revenue $12.1M, vs. Street Est of $10.6M MT
Capricor Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Capricor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Sector Update: Health Care Stocks Ease Late Afternoon MT
Sector Update: Health Care Stocks Decline Tuesday Afternoon MT
Capricor Secures Meeting With FDA on CAP-1002 Manufacturing Plans; Shares Rise MT
Capricor Therapeutics Announces Manufacturing Scale-Up of Cap-1002 Production At New San Diego Facility as It Continues Plans Toward Commercialization CI
Capricor Therapeutics Shares Rise 7% After Collaboration for Covid-19 Vaccine DJ
Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2 CI
Capricor Therapeutics Announces Continuation of Phase 3 Hope-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis CI
Transcript : Capricor Therapeutics, Inc., Q3 2023 Earnings Call, Nov 14, 2023
Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Reports Q3 Revenue $6.2M, vs. Street Est of $3.17M MT
Capricor Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
More news
Managers TitleAgeSince
Chief Executive Officer 60 13-11-19
Director of Finance/CFO 38 13-11-19
Chief Tech/Sci/R&D Officer - 20-12-31
Members of the board TitleAgeSince
Director/Board Member 61 23-07-20
Director/Board Member 76 13-11-19
Director/Board Member 77 13-11-19
More insiders
Capricor Therapeutics, Inc. is a biotechnology company. The Company is focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. The Company's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is in late-stage clinical development for treating Duchenne muscular dystrophy (DMD). CAP-1002 is designed to slow disease progression in DMD through the immunomodulatory, anti-inflammatory, and anti-fibrotic actions of cardiosphere-derived cells (CDCs), which are mediated by secreted exosomes laden with bioactive cargo. CAP-2003 is the name of its exosomes product candidate, which is derived from its CDCs. It is also developing its exosome technology as a therapeutic platform. The Company's focus is on developing exosomes capable of delivering nucleic acids, including messenger RNA (mRNA), as well as proteins to treat or prevent a variety of diseases.
More about the company
  1. Stock
  2. Equities
  3. Stock Capricor Therapeutics, Inc.
  4. Stock Capricor Therapeutics Inc - Nasdaq